Akili Interactive Labs
Akili Interactive Labs is a Boston-based digital therapeutics company that develops FDA-authorized video game-based cognitive treatments, including prescription EndeavorRx for children with ADHD and over-the-counter EndeavorOTC for adults with ADHD, powered by its proprietary adaptive SSME technology platform.
- Company typePublic
- Founded2011
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2C
- OfferingSoftware
What Akili Interactive Labs does
Akili Interactive Labs, founded in 2011 and headquartered in Boston, is a digital therapeutics company that develops software-based cognitive treatments delivered through action video game experiences. The company's flagship product, EndeavorRx, received FDA De Novo authorization in June 2020 as the first prescription video game treatment, indicated to improve attention function in children ages 8-12 with primarily inattentive or combined-type ADHD. In June 2024, Akili received FDA authorization for EndeavorOTC, the first over-the-counter video game-based therapy for adult ADHD. Both products are powered by Akili's proprietary Selective Stimulus Management Engine (SSME), which presents specific sensory stimuli paired with simultaneous motor challenges designed to target neural systems involved in attentional control, using adaptive closed-loop algorithms that personalize treatment difficulty in real time. The company also maintains two additional technology platforms in its pipeline — Body Brain Trainer (BBT) and Spatial Navigation Engine (SNAV) — targeting fronto-parieto-cerebellar and hippocampal neural systems respectively. Akili distributes EndeavorRx exclusively through licensed healthcare provider prescriptions and EndeavorOTC directly to consumers via the Apple App Store and Google Play; the company also holds a CE Mark for Europe and licensing agreements with Shionogi (Japan) and TALi for international markets. Following a SPAC business combination in August 2022 that raised over $163 million, Akili was delisted and acquired by Virtual Therapeutics in July 2024 for approximately $34 million, with 88.2% of shares tendered in the transaction.
Akili Interactive Labs firmographics
Firmographics- Name
- Akili Interactive Labs
- Legal name
- Akili Interactive Labs, Inc.
- Website
- https://akiliinteractive.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Akili Interactive Labs is a Boston-based digital therapeutics company that develops FDA-authorized video game-based cognitive treatments, including prescription EndeavorRx for children with ADHD and over-the-counter EndeavorOTC for adults with ADHD, powered by its proprietary adaptive SSME technology platform.
- Ownership category
- akta.pro rank
Akili Interactive Labs industry classification
Industry- Product category
- Digital Therapeutics
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Pediatrics & Adolescent Therapeutics (Digital) (HLACANAL)
- akta.pro secondary industry
- Executive Functioning & Behavioral Support Tools (ADHD, SEL/Behavior Tracking, Routines) (EDAFAKAG)
Keywords
Where Akili Interactive Labs is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Akili Interactive Labs business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Prescription Digital Therapeutic Sales (EndeavorRx): EndeavorRx is available by prescription only through licensed healthcare providers. Revenue generated from prescription digital therapeutic sales for pediatric ADHD treatment.
- Over-the-Counter Digital Therapeutic Sales (EndeavorOTC): EndeavorOTC is sold directly to consumers through app stores (Apple App Store and Google Play) without prescription for adult ADHD treatment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | EndeavorOTC available over-the-counter through app stores |
Distribution channels3 records
Marketing channels6 records
Akili Interactive Labs product offering
Product offeringCore offering
Akili Interactive Labs develops FDA-authorized digital therapeutics delivered as video game experiences for the treatment of attention deficit hyperactivity disorder (ADHD). The company sells EndeavorRx, a prescription-only video game treatment for children ages 8-12 with primarily inattentive or combined-type ADHD, and EndeavorOTC, an over-the-counter game-based treatment for adults with ADHD. Both products are powered by the company's proprietary Selective Stimulus Management Engine (SSME) technology that uses adaptive algorithms to target neural systems involved in attentional control.
Product overview
Akili Interactive Labs develops a portfolio of digital therapeutics delivered as video game experiences. The company offers two consumer-facing products: EndeavorRx (FDA-authorized prescription treatment for children ages 8-12 with ADHD) and EndeavorOTC (FDA-authorized over-the-counter treatment for adults with ADHD). Both products are powered by Akili's proprietary Selective Stimulus Management Engine (SSME) technology that uses adaptive closed-loop algorithms to automatically adjust difficulty and personalize treatment. The company also maintains additional technology platforms including Body Brain Trainer (BBT) and Spatial Navigation Engine (SNAV) in its development pipeline for cognitive impairments across multiple neurological and psychiatric conditions.
Differentiator
Problem solved
Functional benefit
Brands
- EndeavorRx: FDA-authorized prescription video game treatment for children with ADHD ages 8-12
- EndeavorOTC
Products and services
- EndeavorRx FDA-authorized prescription video game treatment indicated to improve attention function in children ages 8-12 with primarily inattentive or combined-type ADHD. Delivered as an engaging action video game experience using proprietary SSME technology with adaptive difficulty algorithms. Available only through a licensed healthcare provider prescription. Received Conformité Européenne (CE) Mark certification for Europe.
- EndeavorOTC FDA-authorized over-the-counter game-based treatment clinically proven to improve focus and attention in adults with ADHD, available without prescription. Uses the same proprietary SSME technology as EndeavorRx, adapted for adult users. Distributed through Apple App Store and Google Play.
Quantifiable outcome
- Statistically significant improvement in TOVA-ACS attention scores (p<0.0001) in adolescents after 4 weeks of treatment
- +5 more outcomes
Companies that use Akili Interactive Labs
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Akili Interactive Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Akili Interactive Labs partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor and core.
- RobloxminorIntegration of prescription video game treatment (EndeavorRx) with Roblox virtual world platform, announced May 26, 2022. Represents strategic move to expand engagement through virtual world experiences.
- ShionogicoreStrategic licensing agreement for Japan market. Phase 2 study in Japan showed Akili's digital treatment was well-received and improved inattention symptoms in children with ADHD.
- TALiminorStrategic licensing agreement extending Akili portfolio and industry leadership in prescription digital therapeutics for cognitive impairments.
- Weill Cornell MedicinecoreCollaborative research partnership to study digital therapeutic AKL-T01 as treatment for COVID brain fog. Led by Dr. Faith Gunning and Dr. Abhishek Jaywant from Weill Cornell Medicine.
- NewYork-Presbyterian HospitalcoreCollaborative research partnership studying AKL-T01 digital therapeutic for COVID brain fog treatment. Part of academic collaboration for cognitive rehabilitation research.
- Vanderbilt University Medical CentercoreAcademic research partnership led by Dr. James Jackson, Assistant Director of The ICU Recovery Center. Collaboration to study digital therapeutic for COVID brain fog in survivors.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Akili Interactive Labs competitors and assessment
Company assessmentDirect peers
- Click Therapeutics: Click Therapeutics develops prescription digital therapeutics across multiple indications (depression, migraine, smoking cessation) using similar FDA-authorization pathway and adaptive software platform approach as Akili, making it a direct competitor in the DTx commercial landscape.
- Pear Therapeutics: Pear Therapeutics was the pioneering prescription digital therapeutics company (reSET, reSET-O, Somryst) before filing for bankruptcy in 2023—a direct historical peer to Akili in FDA-authorized software-based therapeutics targeting CNS conditions, and serves as a cautionary comparable for the commercial challenges DTx companies face.
- Big Health: Big Health develops FDA-cleared digital therapeutics for insomnia (Sleepio) and anxiety (Daylight), sharing Akili's model of clinically validated, software-delivered behavioral interventions for mental health conditions with similar payer/provider commercialization approaches.
- Mahana Therapeutics: Mahana Therapeutics develops prescription digital therapeutics for conditions including IBS and tinnitus, sharing Akili's model of FDA-authorized software therapeutics with payer/provider distribution—though targeting gastroenterology and ENT rather than neuro/psych conditions.
Emerging players
- Cerebral: Cerebral is a telehealth platform specifically focused on ADHD (alongside anxiety and depression) that diagnoses and prescribes stimulant medication directly to consumers—targeting the same adult ADHD patient pool as EndeavorOTC but via a medication-first rather than software-first model.
- Done. Done (Done First) is an ADHD-focused telehealth company offering diagnosis and prescription stimulant treatment to adults—competing for the same adult ADHD demand that EndeavorOTC targets, with a complementary medication-based rather than digital therapeutic approach.
- Woebot Health: Woebot Health develops AI-powered chatbot-based digital therapeutics for mental health conditions including depression and anxiety—sharing Akili's vision of software-delivered mental health interventions but using conversational AI rather than video game mechanics as the engagement modality.
Broad incumbents
- Headspace Health: Headspace Health (merged with Ginger) offers digital mental health including therapy and self-guided tools for ADHD, anxiety, and depression—broader mental health incumbent with subscription consumer and B2B employer channels that compete for the same consumer attention/wellness spend as EndeavorOTC.
- BetterHelp: BetterHelp is the largest online therapy platform offering subscription-based access to licensed therapists for ADHD, anxiety, and depression—a broad incumbent in digital mental health that competes for the same consumer mental health wallet share as EndeavorOTC, though via human-delivered rather than software-delivered therapy.
- Omada Health: Omada Health is a long-established digital therapeutics company targeting diabetes prevention, hypertension, and musculoskeletal conditions with a similar employer/payer channel model to Akili's prescription DTx approach, though focused on cardiometabolic rather than neuro/psych conditions.
Market position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Akili Interactive Labs social profiles
Digital presenceAkili Interactive Labs compliance and trust
Trust signalCompliance2 records
Akili Interactive Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Akili Interactive Labs leadership team
Management profileNumber of profiles
Profiles6 records
Akili Interactive Labs funding detail
Funding detailFunding overview
Funding rounds8 records
Investors24 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Akili Interactive Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Akili Interactive Labs
What does Akili Interactive Labs do?
Akili Interactive Labs develops FDA-authorized digital therapeutics delivered as video game experiences for the treatment of attention deficit hyperactivity disorder (ADHD). The company sells EndeavorRx, a prescription-only video game treatment for children ages 8-12 with primarily inattentive or combined-type ADHD, and EndeavorOTC, an over-the-counter game-based treatment for adults with ADHD. Both products are powered by the company's proprietary Selective Stimulus Management Engine (SSME) technology that uses adaptive algorithms to target neural systems involved in attentional control.
Is Akili Interactive Labs a public or private company?
Akili Interactive Labs is a public company. It is classified as corporate owned and is currently acquired.
When was Akili Interactive Labs founded?
Akili Interactive Labs was founded in 2011. It employs 51 to 100 people.
Where is Akili Interactive Labs based?
Akili Interactive Labs is headquartered in Boston, United States, in the North America region.
How does Akili Interactive Labs make money?
Two revenue lines are on record. Prescription Digital Therapeutic Sales (EndeavorRx) is the primary driver. The others are over-the-Counter Digital Therapeutic Sales (EndeavorOTC).
Who are Akili Interactive Labs's main competitors?
Direct peers on record are Click Therapeutics, Pear Therapeutics, Big Health and Mahana Therapeutics. Emerging players are Cerebral, Done. and Woebot Health. Broad incumbents are Headspace Health, BetterHelp and Omada Health.
Does Akili Interactive Labs have an API?
No public API is recorded for Akili Interactive Labs.
What industry is Akili Interactive Labs in?
Akili Interactive Labs's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAL, Pediatrics & Adolescent Therapeutics (Digital), with a secondary code of EDAFAKAG, Executive Functioning & Behavioral Support Tools (ADHD, SEL/Behavior Tracking, Routines). Its NAICS code is 5132 and its SIC code is 7372.